S. 5004, Patient Cost-Sharing Parity Mandate. Quorum's AI analysis reads it as a net benefit — and names who gains.
S. 5004 · Net good
What it does
This bill requires health insurance plans to charge patients the same out-of-pocket costs (copays, deductibles, coinsurance) for oral cancer drugs taken at home as they do for intravenous cancer drugs administered in a doctor's office.
The analysis names oral anticancer drug manufacturers — and 1 more group — among the beneficiaries.
The trade-off
Oral cancer drugs may become more attractive to patients due to lower cost-sharing, potentially shifting demand away from intravenous formulations and affecting infusion center utilization and revenue.
Transparency scores 85%, with a medium warning level and no detached riders.
Who is behind it
Filed by Tina Smith. Cosponsored by Jerry Moran.
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.